Immune cell Toll-like receptors (TLRs) recognize conserved microbial components, leading to immune and inflammatory responses. However, TLRs are also expressed in cancer cells, including melanoma cells, which express TLR2-4. TLR4 ligands have received attention as immunotherapies; therefore, we assessed the expression of TLR4 in human melanoma specimens (29 primary lesions and 28 metastatic lesions) representing different types of melanoma. A high percentage (≥ 90%) of melanoma lesions expressed TLR4, as judged by immunohistochemistry. Next, the role of TLR4 in cell proliferation and migration was assessed using the TLR4-positive (TLR4 + ) melanoma cell lines 501mel and 888mel, and TLR4-negative (TLR4 -) 928mel melanoma cells. Lipopolysaccharide (LPS), a TLR4 agonist, increased the proliferation of TLR4 + melanoma cells but not of TLR4 -928mel cells. The proliferation-inducing effect of LPS in 888mel cells was abolished by blockade of TLR4 signaling via treatment with short interfering RNA (siRNA) targeting TLR4 or myeloid differentiation primary response gene 88 (MyD88), a molecule downstream of TLR4. However, knockdown of TLR4 or MyD88 expression did not affect the LPS-induced proliferation of 501mel cells, suggesting that residual TLR4 signaling is sufficient to maintain cell proliferation. By contrast, LPS increased the migration of TLR4 + melanoma cells, and this effect was substantially inhibited by TLR4 or MyD88 knockdown. Furthermore, TLR4 knockdown decreased cell migration even in the absence of LPS, suggesting the presence of an endogenous TLR4 ligand(s) in melanoma cells. TLR4 signaling may contribute to melanoma progression, and caution should be exercised when using TLR4 ligands as adjuvant therapy for cancer.
Introduction
Toll-like receptors (TLRs), which form an evolutionarily conserved family of receptors, play a key role in the detection of invading pathogens and in mounting the antimicrobial immune response (Akira and Takeda 2004) . TLRs recognize microbial-associated molecular patterns, including lipid-based structures such as mycobacterial lipopeptides (TLR2) or lipopolysaccharides (TLR4), and microbial genetic materials such as viral double-stranded RNA (TLR3) or unmethylated CpG islands (TLR9). Binding of their respective ligands leads to intracellular downstream events that culminate in cell activation, cytokine secretion, and resistance against pathogens. Furthermore, TLR activation has antitumor activity through the activation of both innate and adaptive immune responses. Okamoto et al. (2006) used the Streptococcal agent OK-432 to activate TLR4 signaling, which resulted in an interferon-γ-mediated antitumor immune response. In addition, intratumoral injection of the heterodimeric TLR2/6 agonist showed antitumor activity in some models, including breast cancer (Shingu et al. 2003) ; however, this agonist does not affect metastatic melanoma, despite successful stimulation of the immune system.
Many TLR studies have focused on immune cells; however, TLR expression is not restricted to immune cells and is shared by many other cell types, including melanocytes (Yu et al. 2009) , and is maintained after transformation. TLRs are expressed on tumor cells from a wide variety of organs, suggesting that TLR signaling plays a role in tumor development; however, its functional significance remains unclear. TLRs expressed on tumor cells may influence tumor growth and host immune responses.
Human melanoma cells express TLR2, 3, 4, 7, 8, and 9 (Goto et al. 2008; Saint-Jean et al. 2011) , the function of which is not fully understood in cutaneous melanoma. A TLR4 agonist, OK-432, has been used as an immunotherapeutic agent in many types of malignancies, including mel-anoma (Kirkwood et al. 1997) . To explore the effect of TLR4 activation on melanoma cells, TLR4-positive (TLR4 + ) and TLR4-negative (TLR4 -) melanoma cells were used. This study describes TLR4 expression in human melanoma lesions and shows that TLR4 signaling promotes the migration and proliferation of human melanoma cells.
Materials and Methods

Cell culture
Three melanoma cell lines, 501mel, 888mel, and 928mel, all established from Caucasian patients, were used in this study (obtained from Prof. Y. Kawakami, Keio University School of Medicine, Tokyo, Japan). They were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO 2 . Cells were fed twice per week and passaged by exposure to 0.05% trypsin prepared in ethylenediaminetetraacetic acid. Lipo polysaccharide (LPS) was purchased from Sigma (St. Louis, MO, USA).
Immunohistochemical staining
Immunohistochemistry was performed on 5 µm-thick paraffinembedded tissue sections that were deparaffinized in xylene. Rabbit polyclonal antibodies against TLR4 and myeloid differentiation primary response gene 88 (MyD88) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The Envision Plus System (Dako, Carpinteria, CA, USA) was used. Paraffin-embedded archival tissue specimens of melanoma (29 primary tumors and 28 metastatic tumors) were obtained from melanoma patients who underwent surgical resection at Shinshu University Hospital (Nagano, Japan) between 1999 and 2009. The study was approved by the Ethical Committee of Shinshu University School of Medicine and was conducted according to the guidelines set out by the Institutional Review Board.
Cell proliferation assay
After preparing melanoma cell suspensions, cells were seeded in 96-well plates (Nalge Nunc International, Rochester, NY, USA) in RPMI-1640 medium containing 10% FBS. Melanoma cells were incubated in RPMI-1640 medium containing 2% FBS with or without 10 µg/ml LPS for 4 hours, after which LPS was removed and the cells were incubated in RPMI-1640 medium containing 2% FBS for 48 hours. Thereafter, WST-8 solution (Cell Count Reagent SF, Nacalai Tesque, Kyoto, Japan) was added and the optical absorption was measured at 450 nm with a reference wavelength of 650 nm.
Cell migration assay
For migration assays using transwell chambers, melanoma cells were suspended in RPMI-1640 medium containing 2.5% FBS and seeded onto the porous polycarbonate membrane (8.0 µm pores) of a transwell chamber (Corning Incorporated, Corning, NY, USA). The lower chamber was filled with RPMI-1640 medium supplemented with 2.5% FBS in the presence or absence of LPS (10 µg/ml). After incubation for 24 hours, the inserts were removed and the cells that had migrated to the lower chamber were stained with crystal violet after fixation with 80% ethanol. The number of migrated cells was counted in more than ten randomly selected fields with a light microscope.
For migration assays using the scratch method, cells were grown to confluence in 12-well plates and then serum-starved in RPMI-1640 medium for 24 hours. After serum starvation, a scratch was made through the monolayer with a 200-µl pipette tip. Cells were further incubated, and the scratch areas were filled by migrating cells. Images of more than six fields were captured, and migration into the scratch area was analyzed using ImageJ software.
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
Total RNA was extracted from cells using the TRIzol reagent (Invitrogen, Tokyo, Japan), as recommended by the manufacturer. cDNAs were synthesized using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, USA) and 3 µg of total RNA as the template. qRT-PCR analysis was performed with a LightCycler System and the Universal ProbeLibrary Set (Roche Applied Science, Indianapolis, IN, USA). Specific primers were designed to cross exon-exon boundaries by the Universal ProbeLibrary Assay Design Center (Roche Applied Science) as follows: TLR4, 5′-CCATGGCCTTCCTCTCCT-3′ and 5′-TCAGCT CCATGCATTGATAAGT-3′; MyD88, 5′-CTGCTCGAGCTGCTT ACCA-3′ and 5′-CTTTTGGCAATCCTCCTCAA-3′; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5′-GAGTCCACTGGCGTC TTCAC-3′ and 5′-TTCACACCCATGACGAACAT-3′. The Human Universal ProbeLibrary sets #33, #33, and #45 (Roche Applied Science) were used for TLR4, MyD88, and GAPDH, respectively. The expression of TLR4 and MyD88 was normalized to that of GAPDH.
RNA interference
Short interfering RNAs (siRNAs) were designed for TLR4 and MyD88 as follows: TLR4 siRNA#1 (T1), 5′-GGGCAUGCCUGU GCUGAGUUUGAAU-3′; TLR4 siRNA#2 (T2), 5′-GGGUAAGGA AUGAGCUAGUAAAGAA-3′; TLR4 siRNA#3 (T3), 5′-GAGCCU AAGCCACCUCUCUACCUUA-3′; MyD88 siRNA#1 (M1), 5′-AUC GCGGUCAGACACACACAACUUC-3′; and MyD88 siRNA#2 (M2), 5′-UUUCGAUGAGCUCACUAGCAAUAGA-3′. A scrambled siRNA control was purchased from Invitrogen. The siRNAs were transfected using Lipofectamine 2000 (Invitrogen). Block-iT Fluorescent Oligo (Invitrogen) showed that siRNAs were introduced into more than 80% of the melanoma cells.
Statistical analysis
The data were analyzed using the Student's t-test for unpaired observations. Differences were considered significant when p < 0.05.
Results
Most human melanoma lesions express TLR4 and MyD88
Human melanoma cells express various TLRs at the RNA level (Goto et al. 2008; Saint-Jean et al. 2011) . The TLR4 expression of melanomas was assessed in primary tumors (n = 29) and metastatic lesions (n = 28) by immunohistochemistry. Melanoma is classified into five subtypes based on anatomic location and degree of sun exposure: acral lentiginous melanoma, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and mucosal melanoma. The clinical characteristics of the patients are shown in 
TLR4 and MyD88 expression in melanoma cell lines
Having shown that TLR4 is constitutively expressed in a large proportion of human melanoma lesions, we investigated whether TLR4 is functional in melanoma cells. We used three human melanoma cell lines, 501mel, 888mel, and 928mel, the doubling time of which was around 11.16 ± 0.66 hours, 13.66 ± 0.40 hours, and 23.73 ± 1.48 hours, respectively. We evaluated the relative expression levels of TLR4 and MyD88 mRNAs. RT-PCR showed that TLR4 was expressed in 501mel and 888mel cells, but not in 928mel cells (Fig. 2A) . The three cell lines do not show any amplification or deletion at chromosome 9q33.1, which contains the TLR4 gene, by comparative genomic hybridization (Tanami et al. 2004) . Epigenetic alteration may have led to loss of TLR4 expression in 928mel cells. MyD88 was abundantly expressed in the three cell lines (Fig. 2B) . We subsequently used 501mel and 888mel as TLR4 + cell lines and 928mel as a TLR4 -cell line to assess the role of TLR4 in melanoma.
LPS alters the proliferation of melanoma cells
We investigated the effect of TLR4 signaling on melanoma proliferation. LPS, a natural ligand for TLR4, was used to activate TLR4. LPS promoted the proliferation of the TLR4 + cells (501mel and 888mel), but not that of the TLR4 -cells (928mel) (Fig. 3A) . The mitogen-activated protein kinase (MAPK) pathway is one of the main intracellular pathways mediating growth control. We investigated whether TLR4 activation induces MAPK activation in melanoma cells using antibodies specific for phosphorylated MAPK. LPS did not affect the activity of extracellular signal-regulated kinase, c-Jun N-terminal kinase, or p38 MAPK in the melanoma cells, irrespective of whether they expressed TLR4 (data not shown).
To confirm that the increased proliferation induced by LPS is mediated by TLR4 activation, we used siRNA targeting TLR4 or MyD88 to modulate TLR4 signaling (Fig.  3B) . Knockdown of TLR4 expression decreased the proliferation of 888mel cells (Fig. 3C ), but did not substantially affect that of 501mel cells. Similarly, MyD88 knockdown inhibited the proliferation of 888mel cells, but not that of 501mel cells (Fig. 3D, E) . The degree of TLR4 or MyD88 knockdown may be insufficient to inhibit proliferation of 501mel cells i.e., residual TLR4 signaling may be sufficient to maintain the LPS-induced proliferation of these cells. Alternatively, transfection with siRNA can activate the TLR3 pathway in 501mel cells, which may attenuate the effect of the TLR4 knockdown. Although knockdown of TLR4 or MyD88 expression did not substantially attenuate Human melanoma lesions were immunostained with polyclonal antibodies against TLR4 (A) and MyD88 (B) (the primary tumor of patient No. 21 in Table 1 is shown here). Compared to normal epidermis, melanoma lesions expressed TLR4 and MyD88. Arrows show melanoma lesions. Scale bar: 100 µm. the LPS-induced proliferation of 501mel cells, TLR4 activation with LPS promoted proliferation of TLR4 + melanoma cells. It is likely that TLR4 signaling induces the proliferation of melanoma cells.
Melanoma cells migrate in response to LPS
TLR activation promotes leukocyte migration (Fan and Malik 2003) ; therefore, the effect of TLR4 signaling on melanoma cell migration was assessed using transwell chambers. A greater number of TLR4 + cells than TLR4 -cells migrated across the membrane to the lower chamber containing LPS (Fig. 4A) . Furthermore, TLR4 knockdown decreased the migration of 501mel and 888mel cells (Fig.  4B) , as did MyD88 knockdown (Fig. 4C ). In addition, this result indicates that treatment with the siRNA targeting TLR4 or MyD88 can attenuate TLR4 signaling in 501mel cells. On the other hand, MyD88 knockdown did not affect 928mel cell migration. Thus, TLR4 signaling likely promotes melanoma cell migration.
TLR4 regulates melanoma cell migration in the absence of LPS
We investigated whether TLR4 induces melanoma cell migration in response to an endogenous ligand(s) in the absence of LPS. Migration was not detected in the absence of LPS in the transwell assay. By contrast, TLR4 knockdown decreased melanoma cell migration both in the presence (Fig. 5A, B) and absence (Fig. 5C, D) of LPS in the scratch assay, suggesting the existence of an endogenous TLR4 ligand(s). Thus, human melanoma cells show accelerated motility in response to both exogenous and endogenous TLR4 ligands. In addition, TLR4 knockdown did not lead to any dramatic alteration in cellular morphology regardless of the presence of LPS (Fig. 5E and data not shown). How TLR4 signaling activation accelerates melanoma cell migration remains to be elucidated.
Discussion
The present study demonstrates that a large proportion of human melanomas express TLR4. TLR4 activation promotes melanoma cell proliferation, although its contribution may not be robust. Further, TLR4 activation increases melanoma cell migration, which is supported by the fact that knockdown of TLR4 or MyD88 inhibits migration. In addition, TLR4 knockdown delays melanoma cell migration even in the absence of LPS, suggesting the existence of an endogenous TLR4 ligand(s). Thus, melanoma cells use TLR4, a specific defense factor, for their own processes.
The antitumor activity of TLRs is frequently emphasized (Pasare and Medzhitov 2003; Furumoto et al. 2004 ).
In particular, TLR4 supports the development of a strong adaptive immune response (Kasturi et al. 2011) . In murine melanoma cells, TLR4 activation before inoculation significantly inhibits in vivo tumor growth through T cell activation (Andreani et al. 2007; Nunez et al. 2012) . By contrast, other studies suggest that TLR activation induces tumor cell proliferation and promotes angiogenesis, invasion, and metastasis. TLR4 stimulation induces the production of proinflammatory factors, including nitric oxide, interleukin-6, and interleukin-12, in tumor cells. These factors result in the resistance of tumor cells to immune cell attack and in evasion from immune surveillance (Huang et al. 2005) . Furthermore, high TLR4 expression was recently reported to be associated with shortened relapse-free sur- vival in melanoma (Eiro et al. 2013 ) and with disease progression in colon cancer (Wang et al. 2010) . Our results show that TLR4 affects melanoma cell proliferation and motility, although LPS-induced proliferation was not inhibited robustly by TLR4 knockdown. TLR signaling triggers immune cell activation and is indispensable for an efficient immune response against malignant cells. However, when immunosurveillance is unsuccessful against malignant cells, TLR4 expressed on tumor cells may promote tumor cell proliferation, tumor cell migration, or immunosuppression.
The outcome of TLR4 activation may be based on the balance between antitumor and tumorigenic factors. Knockdown of TLR4 or MyD88 suppressed melanoma cell migration even in the absence of LPS, suggesting the existence of an endogenous TLR4 ligand(s). TLRs recognize not only microbial-associated molecular patterns, but also host-derived damage-associated molecular patterns (Medzhitov and Janeway 2002) . Damage-associated molecular patterns derived from injured normal cells and necrotic cancer cells appear to be present at significant levels in the tumor microenvironment, and their stimulation of specific TLRs can foster chronic inflammation (Hiratsuka et al. 2008; Sato et al. 2009) . A variety of endogenous substances, including fibrinogen, hyaluronic acid, and heatshock proteins, can trigger TLR4 signaling. Interestingly, low molecular weight fragments of hyaluronic acid, a degradation product of the extracellular matrix, activate TLR4 signaling in melanoma cells and increase their motility (Voelcker et al. 2008) .
In summary, this study provides evidence of a TLR4 response in melanoma cells, stressing the importance of TLR4 signaling in melanoma progression. TLR4 signaling may promote melanoma progression; therefore, considerable attention is required when using TLR4 ligands as adjuvant therapy. 
